Advancing medicines
Aquestive Therapeutics (formerly MonoSol Rx) is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. Our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. Our initial focus, supported by our current approved products and late stage pipeline, is to address immediate CNS challenges.
A message from Aquestive’s CEO
Over the past decade, we have become the undisputed leader in developing and delivering medications via film through our PharmFilm technology. As our team of scientists and innovators turn their focus to addressing the challenges of complex disease states, Aquestive is ready to transform the landscape of treatment options. Both for our own products, and for products developed in conjunction with partners, Aquestive streamlines and enhances patient care while consistently and efficaciously delivering trusted medications.
Keith J. Kendall
Chief Executive Officer
Meet our team
We are focused problem solvers who work to empower patients and their caregivers. Our team hails from a variety of backgrounds and disciplines, and has created a collaborative culture where different viewpoints are valued and challenging the status quo is the norm.
Board of Directors
We’re fortunate to have experienced industry leaders on our active Board of Directors.
History of success
We have produced over 1.1 billion doses of Suboxone in the last four years and
over 3 billion commercial doses or dose equivalents for all customers since 2008.
2005MonoSol Rx spun off as a separate company from MonoSol LLC
2006Begins development of Suboxone Sublingual Film
2007Multiple products launched with GlaxoSmithKline
2008Begins development of Zuplenz Oral Soluble Film
2010Suboxone receives first FDA approval for sublingual film delivery and drug combination film product
Zuplenz receives first FDA approval for lingual film delivery
Zuplenz receives first FDA approval for lingual film delivery
2013Begins development of its own proprietary CNS products
2016File INDs for diazepam, clobazam, and riluzoleGranted FDA orphan drug designation for Diazepam Buccal Soluble Film
2017Granted FDA fast-track designation for Diazepam Buccal Soluble FilmMonoSol Rx is now Aquestive Therapeutics
